The NM_000540.3:c.14582G>A variant in RYR1 is a missense variant predicted to cause substitution of arginine by histidine at amino acid 4861 (p.Arg4861His). The highest population minor allele frequency in gnomAD v4.1 is 0.0000008475 (1/1180004 alleles) in the European (non-Finnish) population, which is lower than the ClinGen Congenital Myopathies VCEP threshold (absent with 1 allele allowed) for PM2_Supporting, meeting this criterion (PM2_Supporting). The REVEL computational prediction analysis tool gives a score of 0.912, which is above the threshold necessary to apply PP3. Four different missense variants, c.14581C>A (p.Arg4861Ser), c.14581C>G (p.Arg4861Gly), c.14581C>T (p.Arg4861Cys), c.14582G>C (p.Arg4861Pro) (ClinVar IDs: 2027376, 943431, 65986, 1066439), in the same codon have been classified as pathogenic/likely pathogenic for RYR1-related myopathy (PM5). This variant has been reported in at least five probands with RYR1-related myopathy which meets the criteria for PS4, two of which were confirmed to be de novo occurrences meeting PS2 (PMIDs:11709545, 35428369, 35081925). The variant has also been reported to segregate in one affected sibling from a family (PP1, PMID:11709545). Calcium homeostasis analysis of immortalized B-lymphocytes from patients showed significantly smaller thapsigargin-sensitive intracellular calcium stores, compared to lymphoblasts from control individuals, indicating that this variant may impact protein function (PS3_Supporting, PMID:11741831). In summary, the variant meets the criteria to be classified as pathogenic for autosomal dominant RYR1-related myopathy. ACMG/AMP criteria met, as specified by the ClinGen Congenital Myopathies VCEP: PS4, PS2, PS3_Supporting, PM5, PM2_Supporting, PP1, PP3 (ClinGen Congenital Myopathies VCEP specifications version 2; 8/27/2024).